Zacks Research Downgrades Daiichi Sankyo (OTCMKTS:DSNKY) to Strong Sell

Posted by James Quigley on Aug 5th, 2026

Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Monday,Zacks.com reports.

Separately, Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Reduce”.

Get Our Latest Research Report on Daiichi Sankyo

Daiichi Sankyo Trading Down 3.0%

Shares of DSNKY stock opened at $16.00 on Monday. The company has a quick ratio of 1.64, a current ratio of 2.42 and a debt-to-equity ratio of 0.18. Daiichi Sankyo has a 12-month low of $14.98 and a 12-month high of $27.50. The business has a 50-day moving average price of $16.49 and a two-hundred day moving average price of $17.61. The firm has a market cap of $29.81 billion, a P/E ratio of 18.60, a price-to-earnings-growth ratio of 2.89 and a beta of -0.18.

Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). The company had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo had a return on equity of 14.22% and a net margin of 10.92%.Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. Equities analysts anticipate that Daiichi Sankyo will post 0.96 EPS for the current fiscal year.

About Daiichi Sankyo

(Get Free Report)

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.